The significance of the nitric oxide in electro-convulsive therapy: A proposed neurophysiological mechanism

Medical Hypotheses

Volumn 60, Issue 3, 2003, Pages 424-429

  Rosen, Ytzhak ^a,d   Reznik, Ilya ^b,d   Sluvis, Ariel ^c,d   Kaplan, Desmond ^e   Mester, Roberto ^b,d  

^a RABIN MEDICAL CENTER   (Israel)

^b NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINE; CORTICOTROPIN; INTERLEUKIN 1BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

BRAIN BLOOD FLOW; BRAIN METABOLISM; CORTICOTROPIN RELEASE; DEPRESSION; ELECTROCONVULSIVE THERAPY; GLUCOSE METABOLISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM POTENTIATION; MENTAL DISEASE; NEUROMODULATION; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 0037372522     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00419-X     Document Type: Review

References (40)

1. The practice of ECT: recommendations for treatment, training and privileging. Task force report on ECT. Washington DC: American Psychiatric Press, 1990.
2. Abrams R. Electroconvulsive therapy. Oxford: Oxford University Press, 1988.
3. Weiner R. D. Electroconvulsive therapy, 5th edn. In: H. E. Kaplan, B. J. Sadock (eds). Comprehensive Text of Psychiatry. Baltimore MD: Williams and Williams, 1989: 1670-1678.
4. Weiner R. D., Rogers H. J., Davidson J. R. T. et al. Effects of stimulus parameters on cognitive side effects. Ann N Y Acad Sci 1986; 462: 315-325.
5. Squire L. R. Memory functions as affected by electroconvulsive therapy. Ann N Y Acad Sci 1986; 462: 307-314.
6. Miller A. L., Faber R. A., Hatch J. P. et al. Factors affecting amnesia, seizure duration and efficacy in ECT. Am J Psychiatry 1985; 142: 692-696.
7. Sacheim H. A., Portnoy S., Neely P. et al. Cognitive consequences of low-dosage electroconvulsive therapy. Ann N Y Acad Sci 1986; 462: 326-340.
8. Portnoy S. The cognitive side effects of electroconvulsive therapy. Ann N Y Acad Sci 1986; 462: 353-356.
9. Lerer B., Shapira B. Neurochemical mechanisms of mood stabilization focus on electroconvulsive therapy. Ann N Y Acad Sci 1986; 462: 366-375.
10. Fink M., Nemeroff A. A neuroendocrine view of ECT. Convulsive Ther 1989; 5: 296-304.
11. Fink M. Convulsive Therapy: Theory and Practice. New York: Raven Press, 1979.
12. Watkins C. J., Pei Q., Newberry N. R. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res Mol Brain Res 1998; 61: 108-113.
13. Herman J. P., Schafer K. H., Sladek C. D., Day R., Young E. A., Akil H., Watson S. J. Chronic electro-convulsive shock treatment elicits up-regulation of CRF and AVP mRNA in select populations of neuroendocrine neurons. Brain Res 1989; 501: 235-246.
14. Mathe A. A. Neuropeptides and electroconvulsive treatment. J ECT 1999; 15: 60-75.
15. Kling M. A., Geracioti T. D., Licinio J., Michelson D., Oldfield E. H., Gold P. W. Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings. Psychopharmacol Bull 1994; 30: 489-494.
16. Burney S., Tamir S., Gal A., Tannenbaum S. R. A mechanistic analysis of nitric oxide-induced cellular toxicity. Nitric Oxide 1997; 1: 130-144.
17. Brady L. S., Lynn A. B., Glowa J. R., Le D. Q., Herkenham M. Repeated electroconvulsive shock produces long-lasting increases in messenger RNA expression of corticotropin-releasing hormone and tyrosine hydroxylase in rat brain. Therapeutic implications. J Clin Invest 1994; 94: 1263-1268.
18. Dimmeler S., Zaiher A. M. Nitric oxide and apoptosis: another paradigm for the double-edge role of nitric oxide. Nitric Oxide 1997; 1: 275-281.
19. Zdanski C. J., Carrasco V. et al. Inhibition of nitric oxide synthetase cause elevation of hearing thresholds. Otolaryngol Head Neck Surg 1998; 119: 159-163.
20. Karolewicz B. A., Bruce K. H., Lee B., Paul I. A. Nitric oxide synthase inhihitors have anti-depressant-like properties in mice: Chronic treatment results in down-regulation of corticaladrenoceptors. Eur J Pharmacol 1999; 372: 215-220.
21. Bach-y-Rita P. Non-synaptic diffusion neurotransmission (NDN) in the brain. Neurochem Int 1993; 23: 297-318.
22. Stewart C., Jeffery K., Reid I. LTP-like synaptic efficacy changes following electroconvulsive stimulation. Neuroreport 1994; 5: 1041-1044.
23. Reid I. C., Stewart C. A. Seizures, memory, and synaptic plasticity. Harv Rev Psychiatry 1998; 5: 307-317.
24. Rossaint R. Nitric oxide: a new area in intensive care. Presse Med 1994; 123: 855-858.
25. Kling M. A., Geracoti T. D., Licinio J., Michelson D., Oldfield E. H., Gold P. W. Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings. Brain Res 1989; 501: 235-246.
26. Belmont H. M., Levartovsky D., Goel A. et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1810-1816.
27. Shaamash A. H., Elsonosy E. D., Zakhari M. M. et al. Int placental nitric oxide synthase (NOS) activity and nitric oxide (NO) production in normal pregnancy, pre-eclampsia. J Gynaecol Obstet 2001; 72: 127-133.
28. Liu D., Ling X., Wen J., Liu J. The role of reactive nitrogen species in secondary spinal cord injury: formation of nitric oxide, peroxynitrite, and nitrated protein. J Neurochem 2000; 75: 2144-2154.
29. Swanson L. W., Teyler T. J., Thomson R. F. Hippocampal long-term potentiation: Mechanisms and implications for memory. Neurosci Res Prog Bull 1982; 20: 613-769.
30. Madison D. V., Malenka R. C. The role of post-synaptic calcium in the induction of long-term potentiation. Mol Neurobiol 1991; 5: 289-295.
31. Johnston D., Williams S. W., Jaffe D., Gray R. NMDA-receptor independent long-term potentiation. Annu Rev Physiol 1992; 54: 489-505.
32. Cooper J. R., Bloom F. E., Roth R. H. The Biochemical Basis of Neuropharmacologiy, 7th Edn. New York: Oxford University Press, 1996.
33. Bloom F. E., Kupfer D. J. Pharmacology, Fourth Generation of Progress. New York: Raven Press, 1995.
34. Hardman J. G., Limbird L. E. et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edn. New York: McGraw-Hill, 1996.
35. Brown B. L., Dobson P. R. M. Advances in Second messenger and Phosphoprotein Research. New York: Raven Press, 1995.
36. Jansen K. L. Ketamine: can chronic use impair memory? Int J Addict 1990; 25: 133.
37. Johnston D., Miao-Sin W. Foundations of Cellular neurophysiology. London, England: MIT Press, 1995.
38. Naylor P., Stewart C. A., Wright S. R., Pearson R. C., Reid I. C. Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Brain Res Mol Brain Res 1996; 35: 349-353.
39. Stewart C. A., Reid I. C. Ketamine prevents ECS-induced synaptic enhancement in rat hippocampus. Neurosci Lett 1994; 178: 11-14, Erratum in: Neurosci Lett 1996; 210: 218.
40. Bannerman D. M., Chapman P. F., Kelly P. A., Butcher S. P., Morris R. G. Inhibition of nitric oxide synthase does not prevent the induction of long-term potentiation in vivo. J Neurosci 1994; 14: 7415-7425.